Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fmed.2020.00565 http://scihub22266oqcxt.onion/10.3389/fmed.2020.00565 33043032!7527460!33043032     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Front+Med+(Lausanne) 2020 ; 7 (ä): 565 Nephropedia Template TP {{tp|p=33043032|t=2020. Reflections on the Collaborative Fight Against COVID-19 |pdf=|usr=}}{{33043032}} gab.com Text Reflections on the Collaborative Fight Against COVID-19 JO: Front Med (Lausanne) http://www.kidney.de/pget.php?&tw=1&pmid=33043032 #FOAvip Clinical trials to identify efficient treatments against COVID-19 flourish worldwide without much attention to patients' voice so far. As therapeutic interventions in the early phase of the disease are attracting more and more interest, we argue that now is the time to involve patients' organizations in the design of clinical protocols in order to define the most relevant end-points and assess the risk-benefit balance of new therapies. Twit Text FOAVip Reflections on the Collaborative Fight Against COVID-19 ????Front Med (Lausanne) http://www.kidney.de/pget.php?&tw=1&pmid=33043032 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33043032 #FOAvip English Wikipedia <ref>{{Cite pmid|33043032}}</ref> Reflections on the Collaborative Fight Against COVID-19 #MMPMID33043032 Goldman M; Silva M Front Med (Lausanne) 2020[]; 7 (ä): 565 PMID33043032show ga Clinical trials to identify efficient treatments against COVID-19 flourish worldwide without much attention to patients' voice so far. As therapeutic interventions in the early phase of the disease are attracting more and more interest, we argue that now is the time to involve patients' organizations in the design of clinical protocols in order to define the most relevant end-points and assess the risk-benefit balance of new therapies. äReflections on the Collaborative Fight Against COVID-19 (epmc).pdf DeepDyve Pubget Overpricing